Idor­si­a's brain bleed drug flunks PhI­II tri­al, a decade af­ter pre­vi­ous flop

Idor­sia’s long jour­ney with cla­zosen­tan came to an abrupt “un­ex­pect­ed re­sult” Mon­day morn­ing with a Phase III flop.

The Swiss bio­phar­ma said the drug did not meet the main goal of the late-stage RE­ACT study, con­duct­ed in the US, Cana­da and Eu­rope since ear­ly 2019.

The 409-pa­tient tri­al test­ed the in­tra­venous drug’s abil­i­ty to pre­vent com­pli­ca­tions due to de­layed cere­bral is­chemia fol­low­ing aneurys­mal sub­arach­noid he­m­or­rhage (aSAH), in which blood ves­sels in the brain nar­row and blood ac­cu­mu­lates around the brain’s sur­face, which then di­als up the pres­sure on the brain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER